Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 20/20 | 0.79 |
| ▸ | JAK2 | O60674 | 1/20 | 0.69 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.69 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.69 |
| ▸ | JAK1 | P23458 | 1/20 | 0.69 |
| ▸ | FLT3 | P36888 | 1/20 | 0.69 |
| ▸ | HTR2B | P41595 | 1/20 | 0.69 |
| ▸ | CDK9 | P50750 | 1/20 | 0.69 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.69 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.69 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21919480 | 1.00 | IRAK4 (0.79) | IRAK4JAK2MAP4K4NTRK1JAK1 | |
| SCHEMBL21852565 | 1.00 | IRAK4 (0.79) | IRAK4JAK2MAP4K4NTRK1JAK1 | |
| SCHEMBL21852659 | 0.94 | IRAK4 (0.79) | IRAK4JAK2MAP4K4NTRK1JAK1 | |
| SCHEMBL21919622 | 0.94 | IRAK4 (0.79) | IRAK4JAK2MAP4K4NTRK1JAK1 | |
| SCHEMBL21852554 | 0.94 | IRAK4 (0.79) | IRAK4JAK2MAP4K4NTRK1JAK1 | |
| SCHEMBL21852658 | 0.94 | IRAK4 (0.79) | IRAK4JAK2MAP4K4NTRK1JAK1 | |
| SCHEMBL21852552 | 0.94 | IRAK4 (0.79) | IRAK4JAK2MAP4K4NTRK1JAK1 | |
| SCHEMBL21919637 | 0.94 | IRAK4 (0.79) | IRAK4JAK2MAP4K4NTRK1JAK1 | |
| SCHEMBL20594839 | 0.94 | IRAK4 (0.84) | IRAK4JAK2MAP4K4NTRK1JAK1 | |
| SCHEMBL20594597 | 0.94 | IRAK4 (0.84) | IRAK4JAK2MAP4K4NTRK1JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200123166-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2020-04-23 | — | — | US | claimed |
| US-11034698-B2 | Pyrazolo[ 1,5a]pyrimidine derivatives as IRAK4 modulators | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200123166-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034698-B2 | Pyrazolo[ 1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885JAK2 178/4885MAP4K4 59/4885 |
| US-20200123166-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885JAK2 178/4885MAP4K4 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.